Show simple item record

dc.contributor.authorPerry, Mandyen
dc.contributor.authorMcDonald, Timothy J.en
dc.contributor.authorCudmore, Adrianen
dc.contributor.authorAhmad, Tariqen
dc.date.accessioned2016-08-08T11:50:02Z
dc.date.available2016-08-08T11:50:02Z
dc.date.issued2015-11-02
dc.identifier.citationMeasuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory Internationalen
dc.identifier.urihttp://hdl.handle.net/11287/618029
dc.description.abstractThe anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future.en
dc.language.isoenen
dc.publisherClinical Laboratory Internationalen
dc.relation.urlhttp://www.cli-online.com/index.php?id=4173en
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleMeasuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitisen
dc.typeJournal Articleen
dc.identifier.journalClinical Laboratory Internationalen
dc.type.versionPublisheden


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record